By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.
By communicating with oncologists, Flatiron enhances their understanding of potential issues in clinics and how technology can enhance clinical workflow, said Bobby Green, MD, chief medical officer at Flatiron.
Transcript
How important is it for Flatiron to collaborate with oncologists who are at the forefront of care to better understand what features should be included to enhance clinical workflow?
So, if I’ve learned nothing in my 5 plus years at Flatiron, is that you really don’t know what the right things to do are unless you actually talk to the people who are doing it and go spend time with them. So, at Flatiron what that means is talking to oncologists, asking them questions, understanding what their pain points are, going to their clinics, observing what actually happens while they’re seeing patients, and we do a ton of that at Flatiron. We have teams that go out and spend time with practices and understand their workflows. It’s just 1 of those things that there’s no right answer. Different practices do things differently, so you have to assimilate that information and use that sort of frontline experience to better understand—how do you use technology to solve those problems.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More